Login to Your Account

Kadcyla fails to trump SOC in first-line HER2+ breast cancer

By Michael Fitzhugh
Staff Writer

Friday, December 19, 2014

Roche AG unit Genentech Inc. said top-line data from a phase III study of Kadcyla (ado-trastuzumab emtansine) failed to beat the standard of care, Herceptin (trastuzumab) and a taxane.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription